Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Eloralintide

A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

Eli Lilly · Phase 1 · Not yet recruiting · Enrollment 60

NCT07765511

ArmNauseaVomitingDiarrheaDiscontinuationDeaths
Macupatide + placebon/rn/rn/rn/rn/r
Eloralintide + placebon/rn/rn/rn/rn/r
Macupatide Dose A + Eloralintiden/rn/rn/rn/rn/r
Macupatide Dose B + Eloralintiden/rn/rn/rn/rn/r
Placebon/rn/rn/rn/rn/r

A count stays a count. This page does not turn a count into a percent.